Standard Aspirin Dosage Without Vascepa
For cardiovascular risk reduction in patients with elevated triglycerides (≥150 mg/dL) and other risk factors, guidelines like those from the American College of Cardiology recommend low-dose aspirin at 75-81 mg daily for primary prevention in select adults aged 40-70 without high bleeding risk.[1]
Recommended Change With Vascepa
Vascepa (icosapent ethyl) requires a dosage adjustment for concomitant low-dose aspirin use. The prescribing information specifies low-dose aspirin ≤100 mg daily, as higher doses increase bleeding risk when combined with Vascepa.[2] This differs from standard primary prevention, where aspirin up to 162 mg may sometimes be used; with Vascepa, it caps at ≤100 mg to minimize hemorrhage events observed in trials like REDUCE-IT.
Why the Adjustment Is Needed
Vascepa's mechanism—inhibiting triglyceride synthesis and platelet aggregation—amplifies aspirin's antiplatelet effects, raising bleeding risks (e.g., gastrointestinal or intracranial). In REDUCE-IT, patients on low-dose aspirin (≤100 mg) had higher bleeding rates than placebo, but rates stayed low overall (2.7% vs. 2.0%). Higher aspirin doses were excluded from the trial to avoid excess risk.[2][3]
Evidence from REDUCE-IT Trial
The pivotal REDUCE-IT trial (n=8,179) used Vascepa 4g daily with background therapy including low-dose aspirin (≤100 mg) in ~60% of participants. No aspirin dose increase was recommended; instead, monitoring for bleeding was advised. Major adverse cardiovascular events dropped 25% with Vascepa, supporting its approval with this aspirin limit.[3]
Risks of Higher Aspirin Doses
Exceeding 100 mg aspirin with Vascepa elevates serious bleeding risk by 1.5-2x based on trial data and pharmacology. FDA labeling warns against high-dose aspirin (>100 mg) and advises discontinuing if bleeding occurs.[2] Patient reports on forums note bruising or epistaxis at standard low doses.
Alternatives if Bleeding Concerns Arise
Switch to non-aspirin antiplatelets like clopidogrel (if indicated) or pause aspirin under physician guidance. Vascepa can continue alone for triglyceride lowering. For those on higher aspirin pre-Vascepa, titrate down to ≤100 mg before starting.[2]
Who Makes Vascepa and Related Patents
Amarin manufactures Vascepa. Key U.S. patents (e.g., method-of-use for CV risk reduction) expire around 2030, with ongoing litigation delaying generics.[4]
[1] USPSTF Aspirin Use to Prevent Cardiovascular Disease (2022). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication
[2] Vascepa Prescribing Information (Amarin, 2023). https://www.vascepa.com/prescribing-information
[3] NEJM: REDUCE-IT Trial (2019). https://www.nejm.org/doi/full/10.1056/NEJMoa1812792
[4] DrugPatentWatch: Vascepa Patents. https://www.drugpatentwatch.com/p/tradename/VASCEPA